Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer

Zhang,Zhe; Li,Zhi; Deng,Mingming; Liu,Bofang; Xin,Xing; Zhao,Zhenkun; Zhang,Ye; Lv,Qingjie

doi:10.3892/or.2020.7471

Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer

Authors:
- Zhe Zhang
- Zhi Li
- Mingming Deng
- Bofang Liu
- Xing Xin
- Zhenkun Zhao
- Ye Zhang
- Qingjie Lv
View Affiliations

Affiliations: Department of Pathology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China‑Japan Friendship Hospital, Beijing 100029, P.R. China, Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310016, P.R. China, Department of Medical Oncology, The Fourth People's Hospital of Shenyang, Shenyang, Liaoning 110001, P.R. China, The First Laboratory of the Cancer Institute, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: January 17, 2020 https://doi.org/10.3892/or.2020.7471
Pages: 965-974
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paclitaxel is one of the most effective chemotherapy drugs for breast cancer worldwide but 20‑30% patients show primary resistance to the drug. Screening and identification of markers that facilitate effective and rapid prediction of sensitivity to paclitaxel is therefore an urgent medical requirement. In the present study, G protein signaling modulator 2 (GPSM2) mRNA levels were significantly associated with taxane sensitivity in experiments based on the Gene Expression Omnibus (GEO) online database. Immunohistochemical analysis consistently revealed a significant association of GPSM2 protein levels with paclitaxel sensitivity in breast cancer patients. Knockdown of GPSM2 reduced the sensitivity of breast cancer cells to paclitaxel via regulation of the cell cycle. Animal experiments further corroborated our in vitro findings. These results suggest that GPSM2 plays an important role in breast cancer resistance, supporting its utility as a potential target for improving drug susceptibility in patients as well as a marker of paclitaxel sensitivity.

View Figures

View References

1	Harbeck N and Gnant M: Breast cancer. Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
2	Pondé NF, Zardavas D and Piccart M: Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol. 16:27–44. 2019. View Article : Google Scholar : PubMed/NCBI
3	DeMichele A, Yee D and Esserman L: Mechanisms of resistance to neoadjuvant chemotherapy in breast cancer. N Engl J Med. 377:2287–2289. 2017. View Article : Google Scholar : PubMed/NCBI
4	Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004. View Article : Google Scholar : PubMed/NCBI
5	Weaver BA: How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
6	Herbst RS and Khuri FR: Mode of action of docetaxel-a basis for combination with novel anticancer agents. Cancer Treat Rev. 29:407–415. 2003. View Article : Google Scholar : PubMed/NCBI
7	Pucci P, Rescigno P, Sumanasuriya S, de Bono J and Crea F: Hypoxia and noncoding rnas in taxane resistance. Trends Pharmacol Sci. 39:695–709. 2018. View Article : Google Scholar : PubMed/NCBI
8	Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S and Miles D: Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 7:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
9	Turner N, Biganzoli L and Di Leo A: Continued value of adjuvant anthracyclines as treatment for early breast cancer. Lancet Oncol. 16:e362–e369. 2015. View Article : Google Scholar : PubMed/NCBI
10	Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE, Ferguson MJ and Smith G: ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 115:431–441. 2016. View Article : Google Scholar : PubMed/NCBI
11	Poruchynsky MS, Komlodi-Pasztor E, Trostel S, Wilkerson J, Regairaz M, Pommier Y, Zhang X, Kumar Maity T, Robey R, Burotto M, et al: Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. Proc Natl Acad Sci USA. 112:1571–1576. 2015. View Article : Google Scholar : PubMed/NCBI
12	Yang J, Yu Y, Liu W, Li Z, Wei Z and Jiang R: Microtubule-associated protein tau is associated with the resistance to docetaxel in prostate cancer cell lines. Res Rep Urol. 9:71–77. 2017.PubMed/NCBI
13	Du Q, Taylor L, Compton DA and Macara IG: LGN blocks the ability of NuMA to bind and stabilize microtubules. A mechanism for mitotic spindle assembly regulation. Curr Biol. 12:1928–1933. 2002. View Article : Google Scholar : PubMed/NCBI
14	Mochizuki N, Cho G, Wen B and Insel PA: Identification and cDNA cloning of a novel human mosaic protein, LGN, based on interaction with G alpha i2. Gene. 181:39–43. 1996. View Article : Google Scholar : PubMed/NCBI
15	Fukukawa C, Ueda K, Nishidate T, Katagiri T and Nakamura Y: Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells. Genes Chromosomes Cancer. 49:861–872. 2010. View Article : Google Scholar : PubMed/NCBI
16	He XQ, Zhang YF, Yu JJ, Gan YY, Han NN, Zhang MX, Ge W, Deng JJ, Zheng YF and Xu XM: High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway. Tumour Biol. 39:1–10. 2017. View Article : Google Scholar
17	Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Marshall KA, et al: NCBI GEO: Archive for high-throughput functional genomic data. Nucleic Acids Res. 37:D885–D890. 2009. View Article : Google Scholar : PubMed/NCBI
18	Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, et al: A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 305:1873–1881. 2011. View Article : Google Scholar : PubMed/NCBI
19	Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, Chan S, Welcher R and Liu D: Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage breast cancer. Clin Cancer Res. 19:1587–1595. 2013. View Article : Google Scholar : PubMed/NCBI
20	Shoemaker RH: The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 6:813–823. 2006. View Article : Google Scholar : PubMed/NCBI
21	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
22	Deng M, Yu R, Wang S, Zhang Y, Li Z, Song H, Liu B, Xu L, Wang X, Zhang Z, et al: Limb-bud and heart attenuates growth and invasion of human lung adenocarcinoma cells and predicts survival outcome. Cell Physiol Biochem. 47:223–234. 2018. View Article : Google Scholar : PubMed/NCBI
23	Rao DD, Vorhies JS, Senzer N and Nemunaitis J: siRNA vs. shRNA: Similarities and differences. Adv Drug Deliv Rev. 61:746–759. 2009. View Article : Google Scholar : PubMed/NCBI
24	Jasra S and Anampa J: Anthracycline use for early stage breast cancer in the modern era: A review. Curr Treat Options Oncol. 19:302018. View Article : Google Scholar : PubMed/NCBI
25	Ueno NT and Mamounas EP: Neoadjuvant nab-paclitaxel in the treatment of breast cancer. Breast Cancer Res Treat. 156:427–440. 2016. View Article : Google Scholar : PubMed/NCBI
26	Morin X, Jaouen F and Durbec P: Control of planar divisions by the G-protein regulator LGN maintains progenitors in the chick neuroepithelium. Nat Neurosci. 10:1440–1448. 2007. View Article : Google Scholar : PubMed/NCBI
27	Culurgioni S, Mari S, Bonetti P, Gallini S, Bonetto G, Brennich M, Round A, Nicassio F and Mapelli M: Insc:LGN tetramers promote asymmetric divisions of mammary stem cells. Nat Commun. 9:10252018. View Article : Google Scholar : PubMed/NCBI
28	Liu X, Wang J and Sun G: Identification of key genes and pathways in renal cell carcinoma through expression profiling data. Kidney Blood Press Res. 40:288–297. 2015. View Article : Google Scholar : PubMed/NCBI
29	Nowakowska A and Tarasiuk J: Invasion and metastasis of tumour cells resistant to chemotherapy. Postepy Hig Med Dosw (Online). 71:380–397. 2017. View Article : Google Scholar : PubMed/NCBI
30	Kaur R, Kaur G, Gill RK, Soni R and Bariwal J: Recent developments in tubulin polymerization inhibitors: An overview. Eur J Med Chem. 87:89–124. 2014. View Article : Google Scholar : PubMed/NCBI
31	Wiser O, Qian X, Ehlers M, Ja WW, Roberts RW, Reuveny E, Jan YN and Jan LY: Modulation of basal and receptor-induced GIRK potassium channel activity and neuronal excitability by the mammalian PINS homolog LGN. Neuron. 50:561–573. 2006. View Article : Google Scholar : PubMed/NCBI
32	Churchill CD, Klobukowski M and Tuszynski JA: Elucidating the mechanism of action of the clinically approved taxanes: A comprehensive comparison of local and allosteric effects. Chem Biol Drug Des. 86:1253–1266. 2015. View Article : Google Scholar : PubMed/NCBI
33	Needleman DJ, Ojeda-Lopez MA, Raviv U, Ewert K, Miller HP, Wilson L and Safinya CR: Radial compression of microtubules and the mechanism of action of taxol and associated proteins. Biophys J. 89:3410–3423. 2005. View Article : Google Scholar : PubMed/NCBI